SELLAS Life Sciences Group, Inc.
Report additional data from the Phase 2a SLS009 r/r AML trial
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 8 Mar 2024
- Due
- 30 Jun 2024
- Delivered
- May 2024
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“additional data in the second quarter”
What we found
Evidence strength A What the grades mean
The company announced additional preliminary data from the Phase 2a trial of SLS009 in r/r AML in May 2024, which falls within the second quarter deadline.
-
A SELLAS Life Sciences Group, Inc. 10-Q filed 2024-08-13
“In May 2024, we announced additional preliminary data from the Phase 2a trial of SLS009 in r/r AML” ✓ confirmed on the page
Market reaction: the shares moved +3.9% against the S&P 500 over the three sessions around the disclosure (12 Aug 2024 to 15 Aug 2024). What this measures
Checked 1 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- 2 versions
-
Version 1 · original · stated 8 Mar 2024
Deadline 30 Jun 2024 (“in the second quarter”)
-
Version 2 · stated 28 Mar 2024
Deadline 30 Jun 2024 (“1H 2024”) · wording expected
“Phase 2a clinical trial in r/r AML: Additional data expected in 1H 2024.”
-
Version 3 · stated 12 Aug 2025
Deadline 31 Dec 2025 (“Later This Year”) · wording expected
“Full Data Presentation Expected Later This Year”
-
Version 4 · stated 11 Aug 2026
Deadline 31 Dec 2026 (“Q4 2026”) · wording expected
“Topline data expected in Q4 2026.”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- Phase 2a SLS009 r/r AML trial additional data
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you SELLAS Life Sciences Group, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2024-SLS-002028 · Corrections policy